Telephone risk-based eligibility assessment for low-dose CT lung cancer screening.

Autor:	Dickson JL; Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK., Hall H; Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK., Horst C; Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK., Tisi S; Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK., Verghese P; Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK., Mullin AM; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., Teague J; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., Farrelly L; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., Bowyer V; University College London Hospitals NHS Foundation Trust, London, UK., Gyertson K; University College London Hospitals NHS Foundation Trust, London, UK., Bojang F; University College London Hospitals NHS Foundation Trust, London, UK., Levermore C; University College London Hospitals NHS Foundation Trust, London, UK., Anastasiadis T; Tower Hamlets Clinical Commissioning Group, London, UK., Sennett K; Killick Street Health Centre, London, UK., McCabe J; Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK., Devaraj A; Department of Radiology, Royal Brompton Hospital, London, UK.; National Heart and Lung Institute, Imperial College London, London, UK., Nair A; University College London Hospitals NHS Foundation Trust, London, UK., Navani N; Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK.; University College London Hospitals NHS Foundation Trust, London, UK., Callister ME; Department of Respiratory Medicine, Leeds Teaching Hospitals, Leeds, Yorkshire, UK., Hackshaw A; Cancer Research UK and UCL Cancer Trials Centre, University College London, London, UK., Quaife SL; Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Janes SM; Lungs for Living Research Centre, UCL Respiratory, University College London, London, UK s.janes@ucl.ac.uk.; University College London Hospitals NHS Foundation Trust, London, UK.
Jazyk:	angličtina
Zdroj:	Thorax [Thorax] 2022 Oct; Vol. 77 (10), pp. 1036-1040. Date of Electronic Publication: 2022 Jul 21.
DOI:	10.1136/thoraxjnl-2021-218634
Abstrakt:	Eligibility for lung cancer screening (LCS) requires assessment of lung cancer risk, based on smoking history alongside demographic and medical factors. Reliance on individual face-to-face eligibility assessment risks inefficiency and costliness. The SUMMIT Study introduced a telephone-based lung cancer risk assessment to guide invitation to face-to-face LCS eligibility assessment, which significantly increased the proportion of face-to-face attendees eligible for LCS. However, levels of agreement between phone screener and in-person responses were lower in younger individuals and minority ethnic groups. Telephone-based risk assessment is an efficient way to optimise selection for LCS appointments but requires further iteration to ensure an equitable approach. Competing Interests: Competing interests: JLD, CH, ST, HH, PV, JM, AH and SMJ are investigators for the SUMMIT Study within which the present study cohort is embedded. SUMMIT is sponsored and conducted by University College London and funded by GRAIL LLC. through a research grant awarded to SMJ as principal investigator. SLQ collaborates on the SUMMIT study and has received honorarium from Elsevier for writing a book chapter. AN is a member of the advisory board for Aidence BV. AH has received an honorarium for an advisory board meeting for GRAIL, a consultation fee for Evidera Inc for a GRAIL initiated project, and previously owned shares in Illumina. SMJ has received honoraria from Astra Zeneca, BARD1 Bioscience and Jansen for being an Advisory Board Expert and travel to a US conference. SMJ received grant funding from Owlstone for a separate research study and has a family member who is an employee of Astra Zeneca. SMJ has received travel funding for a conference from Takeda and an honorarium for planning and speaking at educational meetings from Astra Zeneca. All authors perceive that these disclosures pose no academic conflict for this study and declare no other relationships or activities that could appear to have influenced the submitted work. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu